Balaji Gandhi Sells 836 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 836 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $26.98, for a total value of $22,555.28. Following the completion of the transaction, the chief financial officer now directly owns 147,673 shares in the company, valued at approximately $3,984,217.54. This represents a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total transaction of $85,018.95.

Phreesia Price Performance

Shares of NYSE:PHR opened at $27.24 on Friday. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.16. The business has a fifty day simple moving average of $23.42 and a 200 day simple moving average of $22.77. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company’s quarterly revenue was up 16.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.58) EPS. On average, equities research analysts predict that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. JMP Securities reiterated a “market outperform” rating and issued a $30.00 price objective on shares of Phreesia in a research note on Tuesday, December 10th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Robert W. Baird reduced their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. KeyCorp lifted their price objective on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. Finally, Truist Financial raised their price target on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $31.00.

Institutional Trading of Phreesia

Large investors have recently made changes to their positions in the company. International Assets Investment Management LLC raised its position in shares of Phreesia by 2,179.7% during the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after purchasing an additional 1,395 shares during the period. Lombard Odier Asset Management USA Corp bought a new stake in Phreesia during the 2nd quarter valued at $202,000. Point72 DIFC Ltd acquired a new position in Phreesia during the second quarter worth $209,000. XTX Topco Ltd bought a new position in shares of Phreesia in the third quarter valued at $247,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Phreesia during the second quarter valued at about $301,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.